Levofloxacin-13C, d3

Levofloxacin-13C, d3 is the 13C- and deuterium labeled Levofloxacin.

Product Specifications

CAS Number

[1261398-33-7]

Product Name Alternative

(-) -Ofloxacin-13C, d3

UNSPSC

12352005

Hazard Statement

H302, H317, H334, H361, H362

Target

Antibiotic; Bacterial; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-immunoregulation

Field of Research

Infection

Purity

98.76

Solubility

10 mM in DMSO|DMSO : 10mg/mL (ultrasonic) |H2O : ≥ 5mg/mL

Smiles

O=C1C2=CC(F)=C(N3CCN(CC3)[13C]([2H])([2H])[2H])C4=C2N(C=C1C(O)=O)[C@@H](C)CO4

Molecular Formula

C17 13CH17D3FN3O4

Molecular Weight

365.38

Precautions

H302, H317, H334, H361, H362

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014.|[3]Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014.|[4]Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86.